SHARE

A supplemental New Drug Application (sNDA) from Merck & Co., Inc. (NYSE:MRK) has won the approval of the US Food and Drug Administration (FDA). Having been put together with other antiemetic medicines, the single-dose EMEND for Injection P/neurokinin-1 (NK1) receptor antagonist has gained the FDA’s clearance to be used for chemotherapy-induced nausea and vomiting (CINV) in grown-up cancer patients.

The results came from a Phase 3 study that was exploring the well-being and effectiveness of single-dose EMEND® (fosaprepitant dimeglumine). The study was one of its kinds that led to the first approval of Emend for Injection to be used the USA. It can be used simultaneously for highly emetogenic chemotherapy (HEC) as well as MEC.

A lot of patients receiving chemotherapy have had a significant burden of nausea and vomiting and despite the exceptional care and support; the two have remained a challenge. But the results of the study presented at the 2015 annual meeting of the American Society of Clinical Oncology were encouraging according to the study principal investigator and chief medical oncologist, Dr. Bernardo L. Rapoport.

The same was supported by Merck Research Laboratories’ Vice President, Stuart Green, who has stated that the expanded indication for Emend for Injection is likely to bring positive changes to the patients. Green says that the building of the research for EMEND for over a decade expresses Merck’s obligation towards helping people with cancer.

Nevertheless, a lot of caution must be exercised when administrating EMEND to patients who are hypersensitive to any constituent of the product. However, in the case of acute reactions after use, it is advisable to discontinue the infusion and instead institute the appropriate medical therapy.

For the longest time possible, Merck has continued to demonstrate its commitment to uphold to the provision of excellent healthcare through its far-reaching policies, programs, partnerships and innovative health solutions. Having been named the global health care leader, its prescriptions, vaccines, biologic therapies, and other health products are distinguished. Its network and customer base are established in more than 140 countries, and it is looking forward to gaining presence in other places.

LEAVE A REPLY